Sofie Notebaert is an experienced drug development project manager with a strong background in managing early development projects in the pharmaceutical industry. Currently serving as Director at argenx since October 2021, Notebaert previously held roles at Galapagos, where responsibilities included leading the early development portfolio and multiple projects related to inflammatory diseases and cystic fibrosis. Prior to Galapagos, Notebaert worked at CMAST and Beta-Cell NV, managing R&D operations and project management for cell therapy development. Notebaert's career began at ThromboGenics NV, where various roles ranged from group leader in cell biology to scientist, contributing to oncology and ophthalmology drug discovery. Sofie Notebaert holds a PhD in Veterinary Sciences and a Master’s in Biochemistry from Ghent University.
This person is not in any teams
This person is not in any offices